Cargando…

Newly Engineered Magnetic Erythrocytes for Sustained and Targeted Delivery of Anti-Cancer Therapeutic Compounds

Cytotoxic chemotherapy of cancer is limited by serious, sometimes life-threatening, side effects that arise from toxicities to sensitive normal cells because the therapies are not selective for malignant cells. So how can they be selectively improved? Alternative pharmaceutical formulations of anti-...

Descripción completa

Detalles Bibliográficos
Autores principales: Cinti, Caterina, Taranta, Monia, Naldi, Ilaria, Grimaldi, Settimio
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3044154/
https://www.ncbi.nlm.nih.gov/pubmed/21373641
http://dx.doi.org/10.1371/journal.pone.0017132
_version_ 1782198691669475328
author Cinti, Caterina
Taranta, Monia
Naldi, Ilaria
Grimaldi, Settimio
author_facet Cinti, Caterina
Taranta, Monia
Naldi, Ilaria
Grimaldi, Settimio
author_sort Cinti, Caterina
collection PubMed
description Cytotoxic chemotherapy of cancer is limited by serious, sometimes life-threatening, side effects that arise from toxicities to sensitive normal cells because the therapies are not selective for malignant cells. So how can they be selectively improved? Alternative pharmaceutical formulations of anti-cancer agents have been investigated in order to improve conventional chemotherapy treatment. These formulations are associated with problems like severe toxic side effects on healthy organs, drug resistance and limited access of the drug to the tumor sites suggested the need to focus on site-specific controlled drug delivery systems. In response to these concerns, we have developed a new drug delivery system based on magnetic erythrocytes engineered with a viral spike fusion protein. This new erythrocyte-based drug delivery system has the potential for magnetic-controlled site-specific localization and highly efficient fusion capability with the targeted cells. Here we show that the erythro-magneto-HA virosomes drug delivery system is able to attach and fuse with the target cells and to efficiently release therapeutic compounds inside the cells. The efficacy of the anti-cancer drug employed is increased and the dose required is 10 time less than that needed with conventional therapy.
format Text
id pubmed-3044154
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-30441542011-03-03 Newly Engineered Magnetic Erythrocytes for Sustained and Targeted Delivery of Anti-Cancer Therapeutic Compounds Cinti, Caterina Taranta, Monia Naldi, Ilaria Grimaldi, Settimio PLoS One Research Article Cytotoxic chemotherapy of cancer is limited by serious, sometimes life-threatening, side effects that arise from toxicities to sensitive normal cells because the therapies are not selective for malignant cells. So how can they be selectively improved? Alternative pharmaceutical formulations of anti-cancer agents have been investigated in order to improve conventional chemotherapy treatment. These formulations are associated with problems like severe toxic side effects on healthy organs, drug resistance and limited access of the drug to the tumor sites suggested the need to focus on site-specific controlled drug delivery systems. In response to these concerns, we have developed a new drug delivery system based on magnetic erythrocytes engineered with a viral spike fusion protein. This new erythrocyte-based drug delivery system has the potential for magnetic-controlled site-specific localization and highly efficient fusion capability with the targeted cells. Here we show that the erythro-magneto-HA virosomes drug delivery system is able to attach and fuse with the target cells and to efficiently release therapeutic compounds inside the cells. The efficacy of the anti-cancer drug employed is increased and the dose required is 10 time less than that needed with conventional therapy. Public Library of Science 2011-02-23 /pmc/articles/PMC3044154/ /pubmed/21373641 http://dx.doi.org/10.1371/journal.pone.0017132 Text en Cinti et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Cinti, Caterina
Taranta, Monia
Naldi, Ilaria
Grimaldi, Settimio
Newly Engineered Magnetic Erythrocytes for Sustained and Targeted Delivery of Anti-Cancer Therapeutic Compounds
title Newly Engineered Magnetic Erythrocytes for Sustained and Targeted Delivery of Anti-Cancer Therapeutic Compounds
title_full Newly Engineered Magnetic Erythrocytes for Sustained and Targeted Delivery of Anti-Cancer Therapeutic Compounds
title_fullStr Newly Engineered Magnetic Erythrocytes for Sustained and Targeted Delivery of Anti-Cancer Therapeutic Compounds
title_full_unstemmed Newly Engineered Magnetic Erythrocytes for Sustained and Targeted Delivery of Anti-Cancer Therapeutic Compounds
title_short Newly Engineered Magnetic Erythrocytes for Sustained and Targeted Delivery of Anti-Cancer Therapeutic Compounds
title_sort newly engineered magnetic erythrocytes for sustained and targeted delivery of anti-cancer therapeutic compounds
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3044154/
https://www.ncbi.nlm.nih.gov/pubmed/21373641
http://dx.doi.org/10.1371/journal.pone.0017132
work_keys_str_mv AT cinticaterina newlyengineeredmagneticerythrocytesforsustainedandtargeteddeliveryofanticancertherapeuticcompounds
AT tarantamonia newlyengineeredmagneticerythrocytesforsustainedandtargeteddeliveryofanticancertherapeuticcompounds
AT naldiilaria newlyengineeredmagneticerythrocytesforsustainedandtargeteddeliveryofanticancertherapeuticcompounds
AT grimaldisettimio newlyengineeredmagneticerythrocytesforsustainedandtargeteddeliveryofanticancertherapeuticcompounds